Floatz logo

Tas-102

Acute Lymphoblastic Leukemia

OHSU Knight Cancer InstituteunclassifiedPhase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
65/ 100

Competitive context

183 Active assets in the Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
THIOGUANINE ANHYDROUS
St. Jude Children's Research Hospital
Phase 4BBB
Daunorubicin
PETHEMA Foundation
Phase 4BB
ASPARAGINASE
Centre Hospitalier Universitaire de Nice
Phase 4BB
PEGASPARGASE
Dana-Farber Cancer Institute
Phase 4BB
VINCRISTINE SULFATE
Children's Oncology Group
Phase 3BB

View all 50 →

Same molecule, other indications

Tas-102 is also rated in:

Stage IV Renal Cell CancerDormant
BB
Indicative ·
68 / 100
View asset →
Stage IV Non-Small Cell Lung Cancer AJCC v7Dormant
BB
Indicative ·
68 / 100
View asset →
Carcinoma, Islet CellDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →